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Stat5es apoptosis resistance in most solid malignant tumors during co-treatment with
chemotherapy agents, such as camptothecin (CAM). In this study, we investigated the mechanism by which
DX reduces chemotherapy efﬁciency in C6-glioma. DX reduced CAM-increased DNA fragmentation and
caspase-3 activation. The DX's protection was negated by RU486, an antagonist of glucocorticoid receptor
(GR). DX itself increased anti-apoptotic gene, Bcl-xL expression, and its transcription factor, signaling
transducer and activator of transcription 5 (Stat5), DNA binding activity and phospho-Stat5 expression. DX
blocked the CAM-decreased Bcl-xL and phospho-Stat5 expression, and Stat5 binding activity. RU486 negated
DX's actions. To determine whether Stat5 regulates Bcl-xL expression in CAM-induced cell death, C6-glioma
was infected with an adenovirus containing a constitutively activated Stat5-GFP (Ad-Stat5ca). Over-
expression of Stat5ca increased Bcl-xL and decreased CAM-induced cell death compared to control
adenovirus infected cells; whereas Stat5 siRNA decreased DX-induced Bcl-xL and increased cell death.
Phospho-Stat5 expression was observed in the nuclear extract by co-immunoprecipitation with an anti-GR
antibody, indicating that Stat5 and GR were interactive and formed a complex in the nuclei. These results
suggest that DX's prevention from CAM-induced apoptosis and RU486's antagonism of DX's protection may
be through Stat5/Bcl-xL signal pathway regulated by a GR.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Glucocorticoids (GCs) such as dexamethasone (DX) are essential in
the treatment of inﬂammatory disorders, such as rheumatoid arthritis,
asthma and dermatitis, autoimmune diseases, tissue edema. These
properties havemade GCs one of themost frequently prescribed drugs
worldwide. Moreover, GCs are commonly used as co-medication in
cancer therapy [1]. In the early 1969s, GCs were introduced for
remission of induction of childhood leukaemia [1]. Subsequently, the
ability of GCs to efﬁciently kill lymphoid cells has led to their inclusion
in all chemotherapy protocols for lymphoid malignancies [2]. GCs are
also widely used as co-medication in cancer therapy for solid
malignant tumors for their effectiveness in treating the malignant
tumor or treatment-related edema, inﬂammation, pain, electrolyte
imbalance, and to stimulate appetite, to prevent nausea and emesis, or
toxic reactions caused by cytotoxic treatment [1,3]. Before, during, and
after chemotherapy for solid malignant tumors, GCs are given at
varying doses to reduce acute toxicity in cancer patients, thus offering
protection against the long-term effects of genotoxic drugs [3].
The cell type speciﬁc pro- and anti-apoptotic effects of GCs and its
potential clinical implications have been mostly unknown until1 314 362 9462.
ll rights reserved.recently. GCs strongly induce apoptosis in cells of the hematological
lineage, but also in some nonhematologic cells such as osteoblasts
[4,5]. In contrast, GCs support survival in several nonhematologic
tissues, such asmammary gland [6,7], ovary [8,9], liver [10], ﬁbroblasts
[11,12], and glioma [13–16]. Depending on the circumstances, GCs
even exhibit pro- or anti-apoptotic potential in the same cell type.
These GC-induced survival effects may become clinically relevant
when they interfere with the effect of chemotherapeutics [17,18].
While mechanisms of the chemotherapy agent, camptothecin's (CAM)
pro-apoptotic signaling are well studied, mechanisms by which GC
plays an anti-apoptotic role in epithelial origin tumor cells are less
well understood.
The most common glucocorticoids prescribed for brain tumors is
dexamethasone (DX) [13,19,20]. DX has a dramatic effect on
symptoms in patients with brain tumors by decreasing the blood-
brain barrier permeability and the regional cerebral blood volume
[21–23]. DX decreased edema in brain tumor may be counteract the
action of vascular endothelial growth factor (VEGF) [24]. DX pre-
treatment has been recently reported to interfere with apoptotic
death in brain tumor cells by the transcriptional activation of a Bcl-xL
gene [13–15,25–27]. Patients treated with the combination of 1,3-Bis
(2-chloroethyl)-1-nitrosourea (BCNU) and a high-dose of methyl-
prednisolone have less effect than those treated with BCNU alone[18]
leading to the claim that the beneﬁcial effects of steroid treatment in
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that it may reduce the efﬁcacy of chemotherapeutic drugs which act
by inducing apoptosis.
Apoptosis, or programmed cell death (PCD), is mainly characterized
by activation of caspases, mitochondrial depolarization, cell volume
loss, chromatic condensation, and nucleosomal DNA fragmentation
[28]. The members of Bcl-2 family of genes are regulators of apoptosis.
The anti-apoptotic members of these proteins, such as Bcl-2 and Bcl-xL,
enhance cell survival, while the pro-apoptotic members, such as Bax
and Bcl-xS, promote cell death [29]. Bcl-xL is a protein that shares
several anti-apoptotic features with Bcl-2, but the Bcl-x promoter is
distinct from the Bcl-2 promoter and is under the control of different
transcriptional activators [13–15,25,26]. Bcl-xL is thought to increase
resistance to chemotherapy by inhibiting apoptosis. In a number of
neoplasms including glioma, the expression of Bcl-xL promotes cell
survival and decreases sensitivity to chemotherapy [14,15].
The signaling transducer and activator of transcription 5 (Stat5)
proteins are transcriptional factors. When activated Stats are dime-
rized and translocated into the nucleus, they bind to speciﬁc DNA
elements, and activate the transcription of responsive genes. Seven
mammalian Stat proteins (Stat1, Stat2, Stat3, Stat4, Stat5A, Stat5B, and
Stat6) have been isolated. Stat5, one of these Stat proteins, is activated
by the IL-2 and 3 family, growth hormone, erythropoietin, and
thrombopoietin [30–32]. Stat5 is also known to play a role in
transcriptional regulation of Bcl-x gene [26,33–38]. Studies on
interaction between Stats and other transcriptional regulators show
that Stat5 may interact with YY-1, Sp1, C/EEPβ and GR [26,35]. The
mechanism by which DX prevents chemotherapy agent-induced
apoptosis has not been fully understood. In this study, we investigated
how Stat5 regulated the chemotherapy agent, CAM-induced apopto-
sis, especially regulated Bcl-xL expression in C6-glioma cells.
2. Materials and methods
All the chemicals were purchased from Sigma (St. Louis, MO)
unless otherwise speciﬁed. Polyclonal rabbit anti-Phospho-Stat5
(Tyr694) antibody was from Cell Signaling, (Beverly, MA). Monoclonal
mouse anti-Stat5 antibody was from BD Transduction Laboratories,
(San Diego, CA). Mouse anti-actin serum and GR antibody were from
Santa Cruz Biotechnology, (Santa Cruz, CA). Secondary anti-mouse
and anti-rabbit antibody conjugated with alkaline phosphatase was
from Promega, (Madision, WI). Rat C6-glioma cells (American Type
Culture Collection, Rockland, MD) were grown in HAM's F-12 medium
(BioWhittaker, Walkersville, MD) supplemented with 15% horse
serum (BioWhittaker, MD), 2.5% fetal bovine serum (BioWhittaker,
MD), 0.15% sodium bicarbonate, 100 U/ml penicillin, and 100 μg/ml
streptomycin (Life technologies, Grand Island, NY).
2.1. Treatment of cells
Camptothecin (topoisomerase I inhibitor), Dexamethasone (DX)
and RU486 (Mifepristone, RU) were dissolved in dimethyl sulfoxide
(DMSO) (10 mM as a stock solution). The ﬁnal concentration of each
drug was 2 μM. The cells were pre-treated with DX and/or RU486
(30 min before DX) for 6 h or indicated time before CAM treatment.
2.2. DNA fragmentation
A Cell Death Detection enzyme-linked immunosorbent assay ELISA
kit (Roche Applied Science, Germany) was used to quantify DNA
fragmentation after induction of cell death. This assay determines the
levels of histone-associated DNA fragments including mono- and
oligonucleosomes in cell lysates [39–41], based on a sandwich-
enzyme-immunoassay protocol using a monoclonal mouse-anti-DNA
and histone antibody. Analysis was performed according to manufac-
turer's instructions.2.3. Caspase-3 activity
Caspase-3 speciﬁc activity was determined by using a colorimetric
CaspACE™ Assay System (Promega) followingmanufacturer's instruc-
tion. Brieﬂy, cells were seeded onto culture plates and treated with DX
and/or RU486with orwithout CAM. Harvested cells were subjected to
cell lysis buffer, incubated on ice for 20 min, and the supernatant
fraction was collected for use as cell extract. The cell extract was
incubated with 50 μM caspase-3 substrate, Ac-DEVE-p-NA for 4 h at
37 °C. The amounts of released pNA were measured in a microplate
reader at 405 nm. Protein concentrations in cell lysate were
determined. Caspase-3 speciﬁc activities were expressed as pmol of
pNA/μg protein/hour.
2.4. Cell death assay
LDH was measured as previously described after various drug
treatments [42].
2.5. Western blot
Cytoplasm and nuclear proteins were isolated from C6-glioma cells
as described previously [43,44]. Samples (30–50 μg of protein) were
electrophoresed onto a 10–12% SDS-PAGE and transferred to poly-
vinylidenediﬂuoride (PVDF)membranes. Themembraneswere blocked
in a TBST buffer containing 20 mM Tris–HCl, 5% nonfat milk, 150 mM
NaCl, and 0.05% Tween 20, pH 7.5, for 1 h at room temperature.
Thereafter, the blot was incubated with a primary mouse anti-Bcl-xL
(1:1000), rabbit anti-phospho Stat5 (1:100), mouse anti-Stat5 (1:200),
or mouse anti-actin antiserum (1:1000), respectively overnight at 4 °C.
The membrane was washed with TBST three times at 10 min intervals,
incubated with the second antibody (anti-rabbit or anti-mouse IgG
conjugated with alkaline phosphatase; 1:5000 dilution) at room
temperature for 1 h, and then washed three times each at 10 min
intervals with TBST. The color reaction was developed by the Blot AP
System according to the technical manual provided by Promega.
2.6. Isolation of nuclear proteins
C6-glioma cells were collected after the treatment. Nuclear
proteins were extracted following the high-salt method previously
described [45]. Homogenization and extraction conditions have been
described in detail elsewhere [43].
2.7. Electrophoretic mobility shift assay (EMSA)
Gel shift assays to assess Stat5 binding activity have been described
in detail elsewhere [43,46]. The following consensus oligonucleotides
were used Stat5: 5′-TTTGGAGAAAGGCATTTCGGAGAAAAG-3′ (sense)
and 3′-AAACCTCTTTCCGTAAAGCCTCTTTTC-5′ (antisense). The oligo-
nucleotide probes were labeled with γ-32P ATP according to Promega
technical bulletin number 106. The binding reactionwas performed in
a total volume of 20 μl containing the binding buffer (10 mM Tris–HCl,
20 mM NaCl, 1 mM DTT, 1 mM EDTA, 5% glycerol, at pH 7.6),
0.0175 pmol of labeled probe (N10,000 cpm), 20 μg of nuclear protein
and 1 μg of poly dIdC. After incubation for 20 min at room
temperature, the mixtures were subjected to electrophoresis in a
nondenaturing 6% polyacrylamide gel at 180 V for 2 h under low ionic
strength conditions. The gel was dried and subjected to autoradio-
graphy as described previously [43,45].
2.8. Quantitative activated Stat5 by ELISA
Stats activities were determined by TransAM Stats family kits from
Active Motif (Carlsbad, CA). All assays were performed following the
manufactory instruction after the nuclear protein extraction [43].
Fig. 1. DX-inhibiting CAM-increased DNA fragmentation depends on pre-exposure time.
C6-glioma was pretreated with DX (2 μM) for 2, 4, 8, 12 and 24 h followed by CAM
(2 μM) treatment for another 20 h. The cell lysate was collected for DNA fragmentation
by ELISA kit. The value expressed as mean±SD with duplicates in three experiments.
⁎Pb0.01 compared DX+CAM treatment to CAM treatment only.
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Full length Stat5a cDNA [47] was obtained by RT-PCR using total
RNA from rat as template. The following oligonucleotide primer pairs
were used for PCR reactions:
5′-AGGTGAACAGCCATGGCGGGC-3′ and 5′-TCAGGACAAG-
GAGCTTCTGGC-3′ for Stat5a. PCR fragments of Stat5a were cloned
into pGEM-T Easy vector (Promega Co). After DNA sequence
veriﬁcation, the fragments were subcloned (see below).
2.10. Construction of constitutively active Stat5 mutant (Stat5ca)
Constitutively active Stat5a was made by mutating histidine 298 to
arginine and serine 710 to phenylalanine from the full length of Stat5a
using site-directed mutagenesis. Histidine 298 is located upstream of
the putative DNA binding domain and serine 710 is located in the
transactivationdomain. Thedoublemutant (H298RandS710F)of Stat5a
from full length Stat5a has been reported to be constitutively active [47].
Mutagenesis was performed using the QuickChange site-directed
mutagenesis kit (200519) from Stratagene. The parental wild-type
plasmidswere removed by digestionwith selective restriction enzymes.
The oligonucleotides used for mutagenesis are as follows: 5′-CGCAGG-
GCTGAGCGCCTG TGCCAGCAG-3′ for H298R, and 5′-GTTTGTCAATGCTT-
TTGCAGATGCTGGAG-3′ for S710F (underlines represent mutated
bases). DNA sequences were veriﬁed.
2.11. Construction of adenovirus vectors
The pMX-IRES-GFP vector [48] was digested with NotI–AfIII to
obtain IRES-GFP, which was then subcloned into NotI–AfIII sites of the
p-Shuttle vector (K1650-1, Clontech). The pGEM-T vector carrying
Stat5ca was digested with NotI–NotI and subcloned into the p-Shuttle
vector. After sequence veriﬁcation, the p-Shuttle vectors (containing
Stat5ca-IRES-GFP and IRES-GFP), were subcloned into the Adeno-X
expression system (Clontech) using PI-SceI and I-Ceu I. The resultant
Adeno-X DNAs containing Stat5 was transformed into E. coli for
ampliﬁcation, and were puriﬁed and analyzed by PCR. Recombinant
Adeno-X viral DNAs were conﬁrmed, and ampliﬁed. The recombinant
Adeno-X DNAs were linearized by digestionwith PacI for transfection.
2.12. Production of adenovirus in mammalian cells
Ten μgof recombinant Adeno-XDNAs carrying Stat5ca-IRES-GFP and
IRES-GFP were used to transfect HEK 293 cells at a density of 2×106 per
60 mm dish with calcium phosphate (K2051-1 Calphos Mammalian
transfection kit, B and D Bioscience). Transfected cells were monitored
with GFP ﬂuorescence. The two adenoviruses were collected from the
transfected 293 cells 10–14 days after transfection and were ampliﬁed
for another 10–14 days for high-titer stocks. To concentrate adenovirus,
we used a BD Adeno-X virus puriﬁcation kit (K1654-1), and titers were
determined by using Adeno-X rapid titer kits (K1653-1, Clontech).
Infectious units (ifu/ml) were calculated for each well as follows:
(infected cells/ﬁeld)×(ﬁelds/well)/volume virus (ml)×(dilution fac-
tor). We obtained titers in the range of 108–1010 ifu/ml.
Infection of C6-glioma with adenovirus: 1×105 C6-glioma cells
grown in plates or dishes for 24 h were infected with the virus for 48 h
at a ﬁnal titer of 107 ifu/ml. The culture medium was changed, and
cultures received various treatments.
2.13. RNA interference
Stat5 siRNA was used to knockdown Stat5 (Qiagen). Duplex siRNA
sequences are as follows: sense (5′-GCAGUCGACGGAUACGUGAdTdT-
3′) and antisense (5′-UCACGUAUCCGUCGACUGCdTdT-3′). A nonspe-
ciﬁc duplex was used as a control siRNA which did not affect Stat5
mRNA levels relative to the untransfected controls. siRNAs in Opti-MEM medium was mixed with lipofectamine 2000 in Opti-MEM
medium (Invitrogen) for 20 min, then added to C6-glioma cultures
(without antibiotics) for 48 h (ﬁnal concentration was 200 nM). After
transfection, the medium was changed to DMEM/F12 and DX (2 μM)
was added for 6 h followed by CAM (2 μM) for 24 h. Cytotoxicity was
measured by LDH and the cells were collected for determining Bcl-xL
protein level.
2.14. Co-immunoprecipitation
Nuclear extract was pre-cleaned with Protein A sepharose and the
proteinwas incubated with a rabbit anti-GR antibody (Santa Cluz, CA)
at a concentration of 2 μg/ml at 4 °C overnight. Protein A sepharose
was added to the antigen–antibody mixture and incubated with a
gentle agitator for another 1–2 h. The immunoprecipitates were
washed with 500 μl of the lysis buffer containing 0.5 M NaCl for three
times and with 500 μl of lysis buffer (without NaCl) once only, then
resuspended and boiled in SDS loading buffer, separated on an 10%
SDS-polyacrylamide gel, transferred to PVDF membrane, and further
analyzed by Western blotting using rabbit anti-phospho-Stat5.
3. Results
3.1. Dexamethasone prevented the CAM-induced DNA fragmentation in a
time-dependent manner
C6-glioma cells treated with CAM increased DNA fragmentation
determined by a Cell Death Detection ELISA kit, which detects the
levels of histone-associated DNA fragments, including mono- and
oligo-nucleosomes in cell lysate. CAM (2 μM) showed a signiﬁcant
increase in DNA fragmentation (23 folds over the control, Fig. 1). DX
(2 μM) pre-treatment interfered with CAM-induced apoptotic death.
The extent of inhibition of CAM-induced DNA fragmentation by DX
was dependent on the time of DX pre-exposure (before CAM) starting
at 4 h and gradually increasing up to 24 h. Pre-treatment with DX for
2 h did not have any protection (Fig. 1). RU 486, a glucocorticoid
receptor antagonist, completely negated the DX protection when
added 30 min prior to DX (Fig. 1).
3.2. Glucocorticoid receptor (GR) regulated the CAM-induced apoptosis
Chemotherapy agent, CAM, has been known to induce tumor cells
apoptosis [10,49–51]. To assess whether GR is involved in regulation of
Fig. 2. GR regulates CAM-induced cell death determined by LDH, caspase-3 activity and
DNA fragmentation. C6-gliomawas pretreatedwith RU (2 μM) for 30min followed byDX
(2 μM) for 6 h and then followed byCAM(2 μM) treatment for another 20 h. Themedium
was collected for LDH assay (A). The LDH levels expressed as % of the control level (each
value-basal (medium only)/control-basal) with triplicates in three experiments. The
cells were collected for assay of caspase-3 activity determined by colorimetric kit (B).
The caspase-3 activity expressed as pNA/ug protein/hr with mean±SD in triplicates of
three experiments. DNA fragmentation was determined by ELISA and was expressed as
enrichment factor with triplicates in three experiments (C). The data were expressed as
mean±SD in triplicates of three experiments. Pb0.01, ⁎ compared CAM to control;
⁎⁎ compared CAM to DX+CAM; ⁎⁎⁎ compared RU+DX+CAM to DX+CAM.
Fig. 3. DX increases Bcl-xL, phospho-Stat5 expression and Stat5 DNA binding activity in
a time-dependent manner. C6-glioma was treated with DX (2 μM) for 1, 2, 3, 4, 6, 8, 12
and 24 h. Cytoplasm proteins for Bcl-xL and Stat5 expression and nuclei protein for
phospho-Stat5 expression were extracted for Western blot analysis blotted with anti-
Bcl-xL (A), Stat5 and Phospho-Stat5 antibodies (B). Densitometry was performed with
Quantity one software (Bio-Red) and expressed as ratio of Bcl-xL/actin and ratio of
phospho-Stat5/Stat5 with mean±SD from three blots (A and B). Stat5 DNA binding
activity in nuclei protein was determined by EMSA (C).
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RU 486 (30 min before DX) with or without CAM. We measured LDH
level in the medium 24 h after CAM treatment. CAM (2 μM)
signiﬁcantly increased LDH release by 6 fold over the control. DX
reduced LDH release and RU486 reversed DX's effect signiﬁcantly
(Fig. 2A). We also measured the caspase-3 activity by the colorimetric
caspase-3 assay with CaspACE™ using Ac-DEVE-p-NA as a substrate.
CAM alone increased caspase-3 activity up to 15.9 pmol pNA/μg/hour,
compared to 3.5 pmol pNA/μg/hour in untreated control cells. DX
completely blocked the CAM-induced caspase-3 activation. RU486
reversed the DX effect (Fig. 2B). DX and RU 486 alone did not have any
signiﬁcant effect on caspase-3 activation. We also determined the
levels of histone-associated DNA fragments. CAM showed signiﬁcantlyincreased DNA fragmentation (26 folds over the control, Fig. 2C),
while DX (2 μM) reduced this effect signiﬁcantly. RU486 reversed the
protective effect of DX (Fig. 2C). DX and RU486 alone did not show any
signiﬁcant toxicity.
3.3. DX increased Bcl-xL expression and Stat5 activation
It has been reported that DX inhibits apoptosis through increasing
Bcl-xL expression in C6-glioma cells [15,52]. In order to compare the
change of Bcl-xL, Phospho-Stat5 and Stat5 binding activity after DX
treatment, we did time-courses for each. We found that DX alone
increased Bcl-xL expression starting at 2 h and gradually increasing up
to 24 h (Fig. 3A). To further study whether Stat5 is involved in the
regulation of DX-up-regulated Bcl-xL expression, we examined
phosphorylated-Stat5 (phospho-Stat5) expression determined by
Western Blot and Stat5 binding activity determined by an electro-
Fig. 4. GR regulates Bcl-xL and phospho-Stat5 expression. C6-glioma was pretreated
with RU (2 μM) for 30 min, DX (2 μM) for 6 h followed by CAM (2 μM) treatment for
another 20–24 h (A). Cytoplasm protein was extracted for Western blotting for Bcl-xL
(A) and Stat5 (B). Nuclear protein was extracted for Phospho-Stat5 expression (B) by
Western blot. Actin served as control for equal loading protein. Densitometry was
performed with Quantity one software (Bio-Red) and expressed by ratio of Bcl-xL/actin
and phospho-Stat5/Stat5 with mean±SD from three blots (A and B). Stat5 activity was
determined by ELISA kit (Active Motif). The value of Stat5 activity (OD) was expressed
as mean±SD (each value minus basal value) with triplicates in two experiments (B).
Pb0.05, ⁎ compared CAM to control; Pb0.01 ⁎⁎ compared DX+CAM to CAM
and ⁎⁎⁎ compared RU+DX+CAM to DX+CAM.
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nucleus was increased at 1 h and declined at 6 h after DX treatment.
Total Stat5 in cytoplasm was not changed 1–24 h after DX treatment
(Fig. 3B). Densitometry assay showed that Bcl-xL levels were
increased gradually and the ratio of phospho-Stat5/Stat5 increased
at 1 h and declined at 6 h (Fig. 3A and B). Stat5 DNA binding activity
was also increased starting at 1 h and declining at 6 h after DX
treatment. The change of Stat5 binding activity by DX was paralleled
to that of the phospho-Stat5 level in the nuclear extract (Fig. 3C).
These results imply that the elevation of Bcl-xL level may be regulated
by activation of its transcription factor, Stat5.
3.4. GR was involved in the CAM altered Bcl-xL expression and
Stat5 activation
C6-glioma cells were treated with CAM (2 μM) for 24 h with and
without pretreatment of DX (6 h) and/or RU486 (30 min before DX).
Bcl-xL and phospho-Stat5 expression was decreased after CAM
treatment. DX blocked the reduction of Bcl-xL expression and the
ratio of phospho-Stat5/Stat5 induced by CAM. RU486 reversed DX's
effects (Fig. 4A and B). We measured Stat5 activity after the same
treatment as above using a sensitive and quantitative transcription
factor ELISA kit (Active Motif). CAM reduced Stat5 activation
signiﬁcantly as compared to the control. DX blocked this effect and
RU486 antagonized the DX's action (Fig. 4C). These results indicate
that GR may be involved in regulation of Stat5/Bcl-xL pathway.
3.5. Overexpression or knockdown of Stat5 on Bcl-xL expression and
cell cytotoxicity
To determine whether Stat5 regulates Bcl-xL expression and
whether Stat5 affects CAM-induced cell death, we constructed
adenoviruses carrying constitutively activated Stat5 gene-GFP
(Ad-Stat5ca) and Ad-GFP only as a control. C6-glioma cells were
infected with the adenoviruses. The transduction efﬁciency was about
80–90% shown as in Fig. 5A. Bcl-xL expression level was higher in the
C6-glioma infected with Ad-Stat5ca than that in the C6 cells infected
with the control virus only in the presence or absence of CAM
treatment (Fig. 5B). Accordingly, CAM-induced cell death was less in
the C6 infected with Ad-Stat5ca than that in C6 infected with the
control Ad-GFP only (Fig. 5C). To further conﬁrm Stat5 regulating
Bcl-xL and cell death, we used siRNA to knockdown Stat5 expression.
Stat5 siRNAs treatment resulted in an attenuation of DX-induced
Bcl-xL (Fig. 5E) detected by Western blot and DX's protective activity
determined by LDH assay (Fig. 5F), concomitant with knockdown of
Stat5 mRNA (Fig. 5D).
3.6. GR was associated with Stat5 in nuclei
Glucocorticoids have been shown to act as a transcriptional co-
activator for Stat5 and enhance Stat5-dependent transcription [53–55].
We examined whether a GR can be physically associated with Stat5 in
C6-glioma cells after DX treatment. Nuclear extracts were prepared and
co-immunoprecipitated with a GR speciﬁc antibody; immunoprecipi-
tates were developed on Western Blots with a phospho-Stat5 speciﬁc
antibody. Untreated cells showed minimal activity of phospho-Stat5
whereas the cells treatedwithDX for 4h increasedphosphorylated Stat5
expression, and declined after 8 h (Fig 6).
4. Discussion
Glucocorticoid (GC) induces resistance to chemotherapy agent-
induced apoptosis in epithelial origin tumor cells. GCs have been
found to interfere with death receptor pathways, such as CD95-I,
TRAIL, FADD and caspase-8 and caspase-3 activities [56]. Pretreatment
with DX prevents chemotherapy-induced depolarization of mitochon-drial membrane potential and caspase-9 activities [39,57]. DX-
mediated suppression of apoptosis in tumor cells has been reported
through a cross-talk between GR and other transcription factors, such
as AP-1, NF-κB, and NF-AT to activate anti-apoptotic genes or inhibit
pro-apoptotic genes [58–60]. DX is also reported to reduce temozo-
lomide (TMZ)-increased calpain activity, the ratio of Bax/Bcl-2 and
apoptosis [16]. Calpain has been known to cleave Stats as functional
Fig. 5. Effect of Constitutively activated Stat5 (Stat5ca) or Stat5 siRNA on CAM-induced cell death. C6-glioma was infected with adenovirus containing constitutively activated Stat5
(Stat5ca)-GFP and control GFP for 24 h and then were treated with CAM (2 μM) for another 24 h. The adenovirus infected cells demonstrated green ﬂuorescence (A). Bcl-xL
expression was detected by Western blot with or without CAM treatment. Densitometry was performed and the data were expressed by ratio of Bcl-xL/actin with mean±SD from
three blots (B). The cell death was measured by LDH assay with or without CAM treatment (C). Stat5 siRNA (200 nM) applied to C6-glioma for 48 h and the cells treated with DX for
6 h followed by CAM. mRNAwas extracted and RT-PCR performed to detect Stat5 mRNA levels (D). The cytoplasmic proteins were extracted for determining Bcl-xL by Western blot
(E). The data were expressed as ratio of Bcl-xL/actin from three blots. The cell death was measured by LDH assay. The LDH levels expressed as % of the control level in three
experiments with triplicates. Pb0.01, ⁎ compared CAM to control; ⁎⁎ compared infection of adeno-Stat5ca+CAM to control adeno-GFP+CAM or compared DX+CAM with or
without Control siRNA with CAM; ⁎⁎⁎ compared Stat5 siRNA+CAM+DX to Control siRNA+CAM+DX.
Fig. 6. GR interacts with Stat5 in nucleus. 500 mg of nuclei protein of C6-glioma was
collected at various times after DX 2 μM treatment and was pre-incubated with anti-GR
antibody (2 μg/ml) overnight. The protein was developed by Western blot with
phospho-Stat5 antibody.
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be another mechanism for DX resistant to chemotherapy. It has not
been reported that Stat5 regulated GCs-induced Bcl-xL expression via
GR in glioma cells. The detailed mechanism for inhibition of apoptosis
by GCs is not fully clear [62,63].
Although it has been known that DX-induced resistance to
chemotherapy agents is via enhancing the anti-apoptotic gene,
Bcl-xL gene in glioma cells [15,52,64] and other solid malignant cells
[65–67]. The mechanism by which DX increases the Bcl-xL level has
not been fully understood. In this study we investigated whether GR is
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glioma cells. Our results showed that DX resisted the CAM-induced
apoptosis depending on the time of DX's pretreatment. In shorter
treatments, such as 2 h prior to CAM, DX did not have any protection
on CAM-induced apoptosis implying the resistance needs some
process to be established. We found that DX treatment for 4–24 h
reduced CAM cytotoxicity. The pre-treated time is similar to others
(8–24 h) [14]. The difference may depend on the concentration of DX.
RU 486 signiﬁcantly reversed DX's protection indicating that GR is
involved in DX's resistance.
Bcl-xL, a member of the Bcl2 family, is an anti-apoptotic gene on
mitochondria. Several transcription factors are present in the Bcl-xL
promoter region, such as NF-kB, Stat3, Stat5, and AP-1. Glucocorticoids
(GCs) have been shown to enhance NF-kB activity in MCF7 breast
cancer cells [62]. In contrast, GCs also inhibit paclitaxel-induced
apoptosis by inhibition of NF-kB activation [68,69]. The role of GC-
regulated NF-kB may be dependent on the cell types. Other
transcription factors, Stat family, including Stat3 and Stat5, promote
uncontrolled growth and survival through the interference of gene
expression, including cyclin D1, c-Myc, Bcl-xL, Mcl-1, and survivin
genes, and thereby contribute to oncogenesis [70]. DX increased
Bcl-xL expression, is in a time-dependent manner. The change in ratio
of phospho-Stat5/Stat5 and Stat5 binding activity were parallel with a
peak time of 3–4 h after DX treatment. Total Stat5 level did not change
suggesting that the transcriptional up-regulation of Bcl-xL may be via
activation of Stat5 phosphorylation and translocation from cytoplasm
to nucleus. Dominant-negative Stat5 or antisense Stat5 inhibits
growth and induces apoptosis in T47D-derived tumors in nude mice
[71] and selected human leukaemic cell lines [72]. Knockdown Stat5
by siRNA decreased Bcl-xL expression and blocked DX's attenuation of
CAM-induced cell death. Our results are in agreement with others.
Growth factor (GH) and prelactin (PRL) protect beta-cells against
cytotoxic cytokines via STAT5-dependent mechanisms possibly at the
level of Bcl-xL [73]. The survival of thrombopoietin-dependent
leukaemia cell line UT-7/TPO and normal megakaryocytic progenitors
is via the induction of Bcl-xL. Thrombopoietin induced the binding of
Stat5 and subunits of nuclear factor kappa B, p50, and c-Rel to the
Bcl-x gene promoter [74].
A relevant role for Stat5 and Bcl-xL has been known as apoptosis-
regulatory proteins in the pathogenesis of lung cancer [38]. Stat5 is
also a molecular regulator of proliferation, differentiation and
apoptosis in hematopoietic cells [48]. To our knowledge, DX increased
Bcl-xL via the activation of Stat5 has not been reported. Whether GR is
involved in regulating Stat5 activation and Bcl-xL expression has not
been explored. Our results in this study showed that the CAM reduced
Bcl-xL and phospho-Stat5 expression, and Stat5 binding activity were
reversed by pre-treatment of DX. RU486 blocked DX's effects
indicating that GR participates in Stat5 activation.
To further conﬁrm that Stat5 mediates Bcl-xL, we applied a
constitutively activated Stat5 mutant to C6-glioma cells with or
without CAM treatment. A constitutively activated Stat5 mutant
(Stat5ca) blocked the CAM-reduced Bcl-xL level in the infected C6-
glioma indicating that Stat5ca regulated Bcl-xL expression directly.
Stat5ca reduced CAM-induced cytotoxicity in the infected C6-glioma
indicating that activation of the Stat5/Bcl-xL pathway reduced C6-
glioma death. In contrast, knockdown of Stat5 by Stat5 siRNA blocked
DX-induced Bcl-xL expression and DX's protection. Therefore, DX
resistance to CAM-induced apoptosis could be via Stat5 activation
leading to Bcl-xL expression suggesting that DX resistance to the CAM-
induced apoptosis may be through activation of the Stat5/Bcl-xL
signaling pathway.
Using a protein co-immunoprecipitation method we showed that
GR and phospho-Stat5 were associated and interacted in C6-glioma
nuclear extracts indicating that GR may cross talk with Stat5 or co-
activate Stat5 enhancing Bcl-xL expression. Immunoprecipitationwith
GR antibody showed that phospho-Stat5 expression was alteredduring the time period of DX treatment. This changewas in agreement
with phospho-Stat5 expression in nuclear extract by Western blot
(Fig. 3) indicating that GR and Stat5 were interacted in the cell nuclei.
In summary, DX treatment resistance to chemotherapy was
through activation of the Stat5/Bcl-xL signaling pathway mediated
by a GR. Therefore, it is necessary to re-evaluate the use of DX in
conjunction with chemotherapy agents in clinical cancer therapy.
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